Biotech Catalyst Screener

Advanced filtering engine for biotech catalysts. Search across 200+ pending PDUFA dates, clinical readouts, and earnings events. Filter by ODIN tier, event type, therapeutic area, market cap, and date range to find your next winner.

Build custom screens in seconds. Find TIER_1 nano-cap PDUFA approvals. Screen for oncology breakout candidates. Identify earnings + PDUFA combos. Export data for backtesting and portfolio tracking.

Screening Filters

ODIN Tier

TIER_1 (85%+), TIER_2 (65–85%), TIER_3 (40–65%), TIER_4 (<40%)

Filter by approval confidence level

Event Type

PDUFA Decision, Phase Readout, Earnings, AdCom, FDA Meeting

Focus on specific catalyst types

Therapeutic Area

Oncology, Immunology, Rare Disease, CNS, Cardiovascular, Infectious Disease, Dermatology

Screen by disease focus

Market Cap

Mega-cap (>$10B), Large ($2–10B), Mid ($500M–2B), Small ($50M–500M), Micro (<$50M)

Target volatility/runup potential

Date Range

Custom start & end dates

Narrow to specific weeks/months

Stock Price

Min & max price per share

Exclude penny stocks or expensive names

Common Screening Strategies

TIER_1 Nano-Cap Runup

Screen for TIER_1 PDUFA approvals with market cap <$50M, coming in next 30 days. These micro-caps often move 20%+ on approval. Early entry = higher upside.

✓ ODIN Tier: TIER_1, ✓ Event Type: PDUFA Decision, ✓ Market Cap: <$50M, ✓ Date Range: Next 30 days

Oncology Breakout Candidates

Find all TIER_1 + TIER_2 cancer drug PDUFAs in Q1–Q2 2026. Oncology has highest baseline approval rates (~70%). Screen by therapeutic area = focused thesis.

✓ Therapeutic Area: Oncology, ✓ ODIN Tier: TIER_1, TIER_2, ✓ Event Type: PDUFA, ✓ Date Range: Q1–Q2

Earnings + PDUFA Combo

Screen for companies with BOTH earnings and PDUFA decisions in same week. Dual catalysts amplify stock moves. Can trade the catalyst pair for bigger swings.

✓ Event Type: Multiple (PDUFA + Earnings), ✓ Date Range: Same week

Phase Readout Opportunities

Find Phase 2 and Phase 3 readouts coming in next 60 days. Earlier-stage readouts are less predictable but offer higher upside. Good for speculative positioning.

✓ Event Type: Phase Readout, ✓ Date Range: Next 60 days

How to Use the Screener

  1. Set ODIN Tier: Decide your confidence threshold. TIER_1 = high conviction; TIER_3 = speculative. Most conservative traders focus on TIER_1 + TIER_2.
  2. Choose Event Type: Are you looking for PDUFA approvals, clinical readouts, earnings, or advisory committee votes? Select what moves the stock.
  3. Filter by Therapeutic Area: Oncology and immunology have higher baseline approval rates. Rare disease = smaller market but niche expertise advantage.
  4. Set Market Cap Range: Large-cap = lower volatility; micro-cap = higher runup potential. Choose based on your risk tolerance and portfolio size.
  5. Narrow by Date Range: Looking for next 2 weeks? Next 3 months? Set your timeframe and see pending catalysts.
  6. Export & Backtest: Download filtered results as CSV. Backtest your screen against historical ODIN scores and stock performance to validate your thesis.

Frequently Asked Questions

How do I find TIER_1 PDUFA events?

Use the Screener and set Tier to TIER_1, Event Type to PDUFA Decision. Sort by date to see which approvals are coming soonest. Each result shows the ODIN score, ticker, drug name, and PDUFA date.

Can I combine multiple filters?

Yes! Filters stack. For example: Tier=TIER_1, Therapeutic Area=Oncology, Market Cap=<$500M, Date Range=March. Results show the intersection—TIER_1 cancer drug approvals coming in March from small companies.

What's the difference between PDUFA Decision and Phase Readout?

PDUFA Decision is an FDA approval/rejection decision. Phase Readout is clinical trial data release (Phase 2 results, Phase 3 topline, etc.). PDUFA dates are more predictable catalysts; phase readouts can swing either way.

Screener Data & Metrics

Total Events Indexed
200+
TIER_1 Events (High Conviction)
40–50
Average ODIN Score
65%
Update Frequency
Daily
Therapeutic Areas Covered
10+
Data Sources
SEC Filings, FDA, Clinical Trials
PDUFA Calendar 2026What Is a PDUFA Date?ODIN EnginePricing & PlansQ1 Oncology PDUFAsGlossary

Important: PDUFA.BIO is not the FDA. ODIN scores are ML model outputs, not financial advice. All investing carries risk. Read full disclaimer →

PDUFA.BIO
Tue Mar 3, 2026
12 this week

Biotech Catalyst Screener

Screen 263+ upcoming biotech catalysts by type, ODIN tier, therapeutic area & date. Find FDA PDUFA dates, phase readouts & earnings for event-driven trading.

Date ▲Type Ticker Drug Indication TA Prob % Tier
Feb 28, 2026PDUFAASNDNavepegritide (TransCon CNP)88.0%TIER_1
Feb 28, 2026PDUFABMRNPALYNZIQ (pegvaliase)92.0%TIER_1
Feb 28, 2026PDUFACHRSIdebenone80.5%TIER_2
Mar 3, 2026 (Est.)EARNEOLSQ4 2025 Earnings—After Market Close
Mar 3, 2026 (Est.)EARNQSIQ4 2025 Earnings—After Market Close
Mar 3, 2026 (Est.)EARNARCTQ4 2025 Earnings—After Market Close
Mar 3, 2026 (Est.)EARNSRRKQ4 2025 Earnings—Before Market Open
Mar 3, 2026 (Est.)EARNMASSQ4 2025 Earnings—Before Market Open
Mar 3, 2026 (Est.)EARNSOPHQ4 2025 Earnings—Before Market Open
Mar 4, 2026 (Est.)EARNVSTMQ4 2025 Earnings—After Market Close
Mar 4, 2026 (Est.)EARNVEEVQ4 2025 Earnings—After Market Close
Mar 4, 2026 (Est.)EARNICCCQ4 2025 Earnings—After Market Close
Mar 4, 2026 (Est.)EARNOCGNQ4 2025 Earnings—Before Market Open
Mar 5, 2026 (Est.)EARNCOOQ4 2025 Earnings—After Market Close
Mar 5, 2026 (Est.)EARNPROFQ4 2025 Earnings—After Market Close
Mar 5, 2026 (Est.)EARNOPRXQ4 2025 Earnings—After Market Close
Mar 5, 2026 (Est.)EARNTNGXQ4 2025 Earnings—Before Market Open
Mar 5, 2026 (Est.)EARNHCMQ4 2025 Earnings—Before Market Open
Mar 6, 2026PDUFABMYDeucravacitinib (Sotyktu)90.7%TIER_1
Mar 9, 2026 (Est.)EARNSTXSQ4 2025 Earnings—After Market Close
Mar 10, 2026 (Est.)EARNBNTXQ4 2025 Earnings—Before Market Open
Mar 11, 2026 (Est.)EARNCTSOQ4 2025 Earnings—After Market Close
Mar 11, 2026 (Est.)RDOUTAARDARD-101 - (HERO)—Phase 3
Mar 11, 2026 (Est.)RDOUTKPTISelinexor (XPORT-MF-034) - (SENTRY)—Phase 3
Mar 11, 2026 (Est.)RDOUTKPTIXPOVIO (selinexor), Pomalidomide and Dexamethasone - (EMN29/XPORT-MM-031)—Phase 3
Mar 11, 2026 (Est.)RDOUTKRYSKB803 - (IOLITE)—Phase 3
Mar 11, 2026 (Est.)RDOUTLLYOrforglipron - (ACHIEVE-4)—Phase 3
Mar 11, 2026 (Est.)RDOUTAVTXAVTX-009 (anti-IL-1β mAb) - (LOTUS)—Phase 2
Mar 11, 2026 (Est.)RDOUTNSRXNS002—Phase 2
Mar 11, 2026 (Est.)RDOUTACIU[18F]ACI-15916 PET in α-synucleinopathies—Phase 1
Mar 11, 2026 (Est.)RDOUTBCYCBicycle Toxin Conjugates zelenectide pevedotin (BT8009) - (Duravelo-2)—Phase 1
Mar 11, 2026 (Est.)RDOUTRLYBRLYB116—Phase 1
Mar 11, 2026 (Est.)RDOUTSEPNSEP-631—Phase 1
Mar 13, 2026 (Est.)EARNMOLNQ4 2025 Earnings—After Market Close
Mar 13, 2026 (Est.)EARNACXPQ4 2025 Earnings—Before Market Open
Mar 16, 2026PDUFAALDXReproxalap1.1%TIER_4
Mar 16, 2026 (Est.)EARNCATXQ4 2025 Earnings—After Market Close
Mar 17, 2026 (Est.)EARNHQYQ4 2025 Earnings—After Market Close
Mar 17, 2026 (Est.)EARNSTIMQ4 2025 Earnings—Before Market Open
Mar 18, 2026 (Est.)EARNHTFLQ4 2025 Earnings—After Market Close
Mar 19, 2026 (Est.)EARNTNONQ4 2025 Earnings—After Market Close
Mar 20, 2026PDUFARYTMImcivree (setmelanotide)44.3%TIER_3
Mar 23, 2026 (Est.)EARNABVXQ4 2025 Earnings—After Market Close
Mar 24, 2026PDUFAGSKLinerixibat93.6%TIER_1
Mar 26, 2026 (Est.)EARNIPHAQ4 2025 Earnings—Before Market Open
Mar 27, 2026 (Est.)RDOUTMLTXNanobody (sonelokimab) - (VELA-TEEN)—Phase 3
Mar 28, 2026PDUFARCKTKresladi (marnetegragene autotemcel)47.4%TIER_3
Mar 29, 2026PDUFALNTHGallium-68 edotreotide86.0%TIER_1
Apr 1, 2026 (Est.)RDOUTHRMYEPX-100 - (ARGUS)—Phase 3
Apr 1, 2026 (Est.)RDOUTVRDNVRDN-003 - (REVEAL-2)—Phase 3
Apr 5, 2026PDUFADNLITividenofusp alfa75.2%TIER_2
Apr 6, 2026PDUFAORCAOrca-T81.7%TIER_2
Apr 8, 2026PDUFABMYOpdivo (nivolumab)92.8%TIER_1
Apr 10, 2026PDUFALLYOrforglipron93.1%TIER_1
Apr 10, 2026PDUFAREPLRP1 (vusolimogene oderparepvec) + Nivolumab70.2%TIER_3
Apr 11, 2026 (Est.)RDOUTABVXObefazimod - (ABTECT)—Phase 3
Apr 11, 2026 (Est.)RDOUTAZNeplontersen - (CARDIO-TTRansform)—Phase 3
Apr 11, 2026 (Est.)RDOUTIONSeplontersen - (CARDIO-TTRansform)—Phase 3
Apr 11, 2026 (Est.)RDOUTIONSAKCEA-TTR-LRx - (CARDIO-TTRansform)—Phase 3
Apr 11, 2026 (Est.)RDOUTLPCNLPCN 1154 (oral brexanolone)—Phase 3
Apr 11, 2026 (Est.)RDOUTNTLALonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)—Phase 3
Apr 11, 2026 (Est.)RDOUTCNTBRademikibart - (Seabreeze STAT Asthma)—Phase 2
Apr 11, 2026 (Est.)RDOUTKPTISelinexor (XPORT-MF-044) - (SENTRY-2)—Phase 2
Apr 11, 2026 (Est.)RDOUTOCSOCS-01 - (DIAMOND-1)—Phase 2
Apr 11, 2026 (Est.)RDOUTBNTXBNT323/DB-1303—Phase 1
Apr 11, 2026 (Est.)RDOUTIMMPIMP761—Phase 1
Apr 13, 2026PDUFATVTXSparsentan35.4%TIER_4
Apr 14, 2026 (Est.)RDOUTMRNATrivalent (mRNA-1403) - (Nova 301)—Phase 3
Apr 18, 2026 (Est.)RDOUTLSTACertepetide (LSTA1) - (BOLSTER)—Phase 2
Apr 18, 2026 (Est.)RDOUTLSTALSTA1 in combination with SoC chemotherapy - (BOLSTER)—Phase 2
Apr 29, 2026 (Est.)RDOUTOCULAXPAXLI (OTX-TKI) - (SOL-1)—Phase 3
Apr 30, 2026PDUFAAXSMAXS-05 (dextromethorphan/bupropion)78.9%TIER_2
Apr 30, 2026 (Est.)RDOUTAZNImfinzi (durvalumab) - (VOLGA)—Phase 3
May 1, 2026 (Est.)RDOUTTNYATN-401 - (RIDGE-1)—Phase 1
May 10, 2026PDUFAARGXVyvgart (efgartigimod alfa-fcab)90.7%TIER_1
May 11, 2026 (Est.)RDOUTBNTXBNT323/DB-1303—Phase 3
May 11, 2026 (Est.)RDOUTEXELXL092 with atezolizumab - (STELLAR-303)—Phase 3
May 11, 2026 (Est.)RDOUTALTPemvidutide - (RECLAIM)—Phase 2
May 11, 2026 (Est.)RDOUTBMEABMF-650 (GLP-131)—Phase 1
May 11, 2026 (Est.)RDOUTGLUEMRT-2359—Phase 1
May 14, 2026 (Est.)RDOUTBIIBIONIS-MAPTRx (ISIS 814907; BIIB080) - (CELIA)—Phase 2
May 14, 2026 (Est.)RDOUTIONSIONIS-MAPTRx (ISIS 814907; BIIB080) - (CELIA)—Phase 2
May 15, 2026PDUFAAZNBaxdrostat94.0%TIER_1
May 18, 2026PDUFADSKYFT-DXd (trastuzumab deruxtecan)94.1%TIER_1
May 24, 2026PDUFALLYLecanemab SC Autoinjector (Leqembi)95.5%TIER_1
May 30, 2026 (Est.)RDOUTMBXMBX 4291—Phase 1
May 31, 2026PDUFACINGCTx-1301 (dexmethylphenidate)65.1%TIER_3
Jun 2, 2026PDUFAAZNDatopotamab deruxtecan (DATROWAY)94.1%TIER_1
Jun 5, 2026PDUFAARVSVepdegestrant88.5%TIER_1
Jun 11, 2026 (Est.)RDOUTGNLXOlvimulogene Nanivacirepvec (Olvi-Vec) - (OnPrime/GOG-3076)—Phase 3
Jun 11, 2026 (Est.)RDOUTRVMDDaraxonrasib (RMC-6236) - (RASolute 302)—Phase 3
Jun 11, 2026 (Est.)RDOUTBIVIBezisterim (NE3107) - (ADDRESS-LC)—Phase 2
Jun 11, 2026 (Est.)RDOUTEWTXEDG-7500 - (CIRRUS-HCM)—Phase 2
Jun 11, 2026 (Est.)RDOUTMIRMVolixibat - (VISTAS)—Phase 2
Jun 11, 2026 (Est.)RDOUTQTTBBempikibart - (SIGNAL-AA)—Phase 2
Jun 11, 2026 (Est.)RDOUTSYRESPY001, SPY002, SPY003 - (SKYLINE)—Phase 2
Jun 11, 2026 (Est.)RDOUTZBIOObexelimab - (SunStone)—Phase 2
Jun 11, 2026 (Est.)RDOUTACIUACI-24 (anti-Abeta vaccine) - (ABATE)—Phase 1
Jun 11, 2026 (Est.)RDOUTACIUACI-24 (anti-Abeta vaccine)—Phase 1
Jun 11, 2026 (Est.)RDOUTBRNSVTP-1000 - (AVALON)—Phase 1
Jun 11, 2026 (Est.)RDOUTCLYDVTP-1000 - (AVALON)—Phase 1
Jun 11, 2026 (Est.)RDOUTSIONSION-451 + Galicaftor (SION-2222)—Phase 1
Jun 11, 2026 (Est.)RDOUTTAKACI-24 (anti-Abeta vaccine) - (ABATE)—Phase 1
Jun 20, 2026PDUFAACHVCytisinicline44.4%TIER_3
Jun 27, 2026 (Est.)RDOUTWVEWVE-N531 - (FORWARD-53)—Phase 2
Jun 30, 2026PDUFAVRDNVeligrotug79.4%TIER_2
Jun 30, 2026 (Est.)RDOUTAZNDurvalumab in combination with monalizumab or oleclumab - (PACIFIC-9)—Phase 3
Jun 30, 2026 (Est.)RDOUTCELCGedatolisib with Fulvestrant - (VIKTORIA-1)—Phase 3
Jun 30, 2026 (Est.)RDOUTIPHADurvalumab in combination with monalizumab or oleclumab - (PACIFIC-9)—Phase 3
Jun 30, 2026 (Est.)RDOUTJNJNBTXR3 - (NANORAY-312)—Phase 3
Jun 30, 2026 (Est.)RDOUTLIANNBTXR3 with Cetuximab - (NANORAY-312)—Phase 3
Jun 30, 2026 (Est.)RDOUTNBTXNBTXR3 with Cetuximab - (NANORAY-312)—Phase 3
Jun 30, 2026 (Est.)RDOUTDNTHDNTH103 - (MoMeNtum)—Phase 2
Jun 30, 2026 (Est.)RDOUTENGNDetalimogene voraplasmid (EG-70) - (LEGEND)—Phase 2
Jun 30, 2026 (Est.)RDOUTLGVNLaromestrocel (lomecel-B) - (ELPIS II)—Phase 2
Jun 30, 2026 (Est.)RDOUTCLLSUCART22 - (BALLI-01)—Phase 1
Jul 1, 2026PDUFAKURATipifarnib84.7%TIER_2
Jul 1, 2026 (Est.)PH3GSKVaricella vaccine (investigational)—Phase 3
Jul 1, 2026 (Est.)RDOUTHOWLWTX-124—Phase 1
Jul 6, 2026 (Est.)PH3MRKPembrolizumab combos—Phase 3
Jul 7, 2026PDUFAVERAAtacicept47.8%TIER_3
Jul 11, 2026PDUFACORTRelacorilant87.4%TIER_1
Jul 11, 2026 (Est.)RDOUTRAREGTX-102 - (Aspire)—Phase 3
Jul 11, 2026 (Est.)RDOUTSNGXHyBryte - (FLASH2)—Phase 3
Jul 11, 2026 (Est.)RDOUTDWTXHalneuron - (HALT-CINP / HAL-CINP-203)—Phase 2
Jul 11, 2026 (Est.)RDOUTSIONSION-719 - (PreciSION CF)—Phase 2
Jul 11, 2026 (Est.)RDOUTPYXSPYX-201-101 - (MICVO)—Phase 1
Jul 14, 2026 (Est.)PH3REGNMibavademab—Phase 3
Jul 14, 2026 (Est.)PH3AZNTezepelumab—Phase 3
Jul 15, 2026 (Est.)PH3LLYLebrikizumab—Phase 3
Jul 15, 2026 (Est.)PH3HRMYPitolisant—Phase 3
Jul 15, 2026 (Est.)PH3RAREGTX-102—Phase 3
Jul 15, 2026 (Est.)PH3VRDNVRDN-003—Phase 3
Jul 15, 2026 (Est.)RDOUTCANFNamodenoson - (CF102-222PC)—Phase 2
Jul 31, 2026 (Est.)RDOUTJAZZZiihera (zanidatamab-hrii) - (HERIZON-GEA-01)—Phase 3
Jul 31, 2026 (Est.)RDOUTONCZiihera (zanidatamab-hrii) - (HERIZON-GEA-01)—Phase 3
Jul 31, 2026 (Est.)RDOUTZYMEZiihera (zanidatamab-hrii) - (HERIZON-GEA-01)—Phase 3
Jul 31, 2026 (Est.)RDOUTBCYCBT5528 and OPDIVO (nivolumab)—Phase 1
Aug 1, 2026 (Est.)PH3MRKTulisokibart (IV+SC)—Phase 3
Aug 1, 2026 (Est.)PH3BMRNVosoritide—Phase 3
Aug 5, 2026PDUFAMRNAmRNA-1010 (Seasonal Influenza Vaccine)88.7%TIER_1
Aug 6, 2026PDUFACAPRCAP-1002 (deramiocel)7.3%TIER_4
Aug 11, 2026 (Est.)RDOUTKPTIXPOVIO (selinexor) - (XPORT-EC-042)—Phase 3
Aug 11, 2026 (Est.)RDOUTPHVSDeucrictibant (PHVS416) - (CHAPTER-3)—Phase 3
Aug 11, 2026 (Est.)RDOUTRNADelpacibart Etedesiran (del-desiran) - (HARBOR)—Phase 3
Aug 11, 2026 (Est.)RDOUTSLGLSGT-610 (patidegib)—Phase 3
Aug 11, 2026 (Est.)RDOUTBCYCBT7480 with nivolumab—Phase 1
Aug 11, 2026 (Est.)RDOUTKURAziftomenib in combination with gilteritinib (KOMET-008)—Phase 1
Aug 11, 2026 (Est.)RDOUTKYTXKYV-101—Phase 1
Aug 11, 2026 (Est.)RDOUTNCNANUC-7738 (NuTide:701) in combination with pembrolizumab—Phase 1
Aug 12, 2026 (Est.)RDOUTACRVACR-2316—Phase 1
Aug 15, 2026PDUFAREGNGaretosmab94.6%TIER_1
Aug 15, 2026PDUFAGDRMRelabotulinumtoxinA92.4%TIER_1
Aug 15, 2026 (Est.)RDOUTMRKRezatapopt (PC14586) - (PYNNACLE)—Phase 2
Aug 15, 2026 (Est.)RDOUTPMVPRezatapopt (PC14586) - (PYNNACLE)—Phase 2
Aug 17, 2026PDUFABRNCAdrabetadex85.9%TIER_1
Aug 17, 2026PDUFABMYIberdomide (CC-220)89.4%TIER_1
Aug 18, 2026PDUFAHBIOImlifidase (IDEFIRIX)82.3%TIER_2
Aug 18, 2026 (Est.)RDOUTAZNCOM902 (AZD2936) - (ARTEMIDE-01)—Phase 1
Aug 18, 2026 (Est.)RDOUTCGENCOM902 (AZD2936) - (ARTEMIDE-01)—Phase 1
Aug 22, 2026PDUFASVRAMolbreevi (molgramostim)87.1%TIER_1
Aug 23, 2026PDUFARAREDTX401 (pariglasgene autotemcel)89.5%TIER_1
Aug 28, 2026PDUFAPrivate177Lu-edotreotide73.8%TIER_2
Aug 30, 2026PDUFAPHARBesremi (ropeginterferon alfa-2b)15.7%TIER_4
Aug 30, 2026 (Est.)RDOUTHCMORPATHYS (savolitinib) and TAGRISSO (osimertinib) - (SANOVO)—Phase 3
Aug 31, 2026 (Est.)RDOUTVSTMVS-6766 and defactinib - (RAMP 205)—Phase 1
Sep 1, 2026PDUFATAKOveporexton (TAK-861)91.8%TIER_1
Sep 1, 2026 (Est.)PH2NVOSemaglutide—Phase 2
Sep 1, 2026PDUFANVOAwiqli (insulin icodec)89.9%TIER_1
Sep 1, 2026 (Est.)RDOUTNVSMONJUVI (tafasitamab) - (frontMIND)—Phase 3
Sep 2, 2026 (Est.)PH3AMGNDazodalibep—Phase 3
Sep 3, 2026 (Est.)PH3NVOZiltivekimab—Phase 3
Sep 3, 2026 (Est.)PH3UCBJYFenfluramine—Phase 3
Sep 5, 2026 (Est.)PH3HLUYYEptinezumab—Phase 3
Sep 11, 2026 (Est.)RDOUTHCMSovleplenib - (China trial)—Phase 3
Sep 11, 2026 (Est.)RDOUTHCMSovleplenib - (ESLIM-02)—Phase 3
Sep 11, 2026 (Est.)RDOUTBHVNTaldefgrobep alfa—Phase 2
Sep 11, 2026 (Est.)RDOUTEWTXSevasemten (EDG-5509) - (GRAND CANYON)—Phase 2
Sep 11, 2026 (Est.)RDOUTNVSTOUR006 - (spiriTED)—Phase 2
Sep 11, 2026 (Est.)RDOUTORKAORKA-001 - (EVERLAST-A)—Phase 2
Sep 11, 2026 (Est.)RDOUTPCSANGC-Capecitabine (PCS6422)—Phase 2
Sep 11, 2026 (Est.)RDOUTPFETaldefgrobep alfa—Phase 2
Sep 11, 2026 (Est.)RDOUTSLNDivesiran (SLN124) - (SANRECO)—Phase 2
Sep 11, 2026 (Est.)RDOUTSNDXNiktimvo (axatilimab-csfr) - (MAXPIRe)—Phase 2
Sep 11, 2026 (Est.)RDOUTTRMLTOUR006 - (spiriTED)—Phase 2
Sep 11, 2026 (Est.)RDOUTDTILECUR-506 - (OTC-HOPE)—Phase 1
Sep 11, 2026 (Est.)RDOUTIRONDISC-0974—Phase 1
Sep 11, 2026 (Est.)RDOUTORICEnozertinib (ORIC-114)—Phase 1
Sep 18, 2026PDUFANUVLZidesamtinib75.0%TIER_2
Sep 28, 2026PDUFAAMZLAminolevulinic acid + RhodoLED85.2%TIER_2
Sep 30, 2026 (Est.)RDOUTAZNDatopotamab deruxtecan with or without osimertinib - (TROPION-Lung15)—Phase 3
Sep 30, 2026 (Est.)RDOUTBMRNBMN 351—Phase 1
Sep 30, 2026 (Est.)RDOUTQUREAMT-162—Phase 1
Oct 1, 2026 (Est.)PH3ARGXEfgartigimod PH20 SC—Phase 3
Oct 1, 2026PDUFANVOCagriSema89.9%TIER_1
Oct 5, 2026 (Est.)PH3NVOZiltivekimab—Phase 3
Oct 6, 2026 (Est.)PH3AZNBenralizumab—Phase 3
Oct 9, 2026 (Est.)PH3INCYRuxolitinib Cream—Phase 3
Oct 10, 2026PDUFAPrivateTabelecleucel35.1%TIER_4
Oct 11, 2026 (Est.)RDOUTEYPTDURAVYU (EYP-1901) - (LUCIA)—Phase 3
Oct 11, 2026 (Est.)RDOUTLLYJaypirca (pirtobrutinib) - (BRUIN CLL-322)—Phase 3
Oct 11, 2026 (Est.)RDOUTTENXTNX-103 (oral levosimendan) - (LEVEL)—Phase 3
Oct 11, 2026 (Est.)RDOUTABOSACU193 - (ALTITUDE-AD)—Phase 2
Oct 11, 2026 (Est.)RDOUTRAPPRAP-219—Phase 2
Oct 11, 2026 (Est.)RDOUTRGNXSurabgene lomparvovec (sura-vec, ABBV-RGX-314) - (ASCENT)—Phase 2
Oct 11, 2026 (Est.)RDOUTRNADelpacibart braxlosiran (del-brax) - (FORTITUDE)—Phase 2
Oct 11, 2026 (Est.)RDOUTBCRXBCX17725—Phase 1
Oct 30, 2026PDUFAINOINO-310767.8%TIER_2
Oct 31, 2026 (Est.)RDOUTBMYMilvexian - (Librexia AF)—Phase 3
Oct 31, 2026 (Est.)RDOUTJNJMilvexian - (Librexia AF)—Phase 3
Oct 31, 2026 (Est.)RDOUTACRVACR-368—Phase 2
Oct 31, 2026 (Est.)RDOUTADAGmuzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98)—Phase 2
Oct 31, 2026 (Est.)RDOUTANNXANX007 - (ARCHER-II)—Phase 2
Oct 31, 2026 (Est.)RDOUTSYRESPY072 - (SKYWAY-RD, basket study)—Phase 2
Oct 31, 2026 (Est.)RDOUTSDGRSGR-3515—Phase 1
Nov 1, 2026 (Est.)PH3SRRKApitegromab—Phase 3
Nov 11, 2026 (Est.)RDOUTBMYMilvexian - (Librexia STROKE)—Phase 3
Nov 11, 2026 (Est.)RDOUTCRVSSoquelitinib - (CPI-818)—Phase 3
Nov 11, 2026 (Est.)RDOUTJNJMilvexian - (Librexia STROKE)—Phase 3
Nov 11, 2026 (Est.)RDOUTLLYOrforglipron - (ATTAIN-OSA)—Phase 3
Nov 11, 2026 (Est.)RDOUTBNTXAutogene cevumeran (BNT122/RO7198457)—Phase 2
Nov 11, 2026 (Est.)RDOUTCRDFCRDF-004—Phase 2
Nov 11, 2026 (Est.)RDOUTELTXELI-002 - (AMPLIFY-7P)—Phase 2
Nov 11, 2026 (Est.)RDOUTPFECRDF-004—Phase 2
Nov 11, 2026 (Est.)RDOUTABCLABCL575—Phase 1
Nov 14, 2026PDUFASMMTIvonescimab25.2%TIER_4
Nov 20, 2026 (Est.)RDOUTSKYENimacimab - (CBeyond)—Phase 2
Dec 1, 2026 (Est.)PH3SNYItepekimab—Phase 3
Dec 1, 2026 (Est.)PH3ARGXEfgartigimod PH20 SC—Phase 3
Dec 1, 2026 (Est.)PH3SNYPCV21—Phase 3
Dec 1, 2026PDUFAJNJIcotrokinra93.7%TIER_1
Dec 1, 2026 (Est.)RDOUTZNTLAzenosertib (ZN-c3) + ZEJULA (Niraparib) - (DENALI)—Phase 2
Dec 2, 2026 (Est.)PH3PFEPF-06821497 (mevrometostat)—Phase 3
Dec 3, 2026PDUFAEXELZanzalintinib + Atezolizumab87.7%TIER_1
Dec 11, 2026 (Est.)RDOUTNVOZaltenibart - (OMS906)—Phase 3
Dec 11, 2026 (Est.)RDOUTOMERZaltenibart - (OMS906)—Phase 3
Dec 11, 2026 (Est.)RDOUTANROALTO-300—Phase 2
Dec 11, 2026 (Est.)RDOUTCLSDSurabgene lomparvovec (sura-vec, ABBV-RGX-314) - (ATMOSPHERE)—Phase 2
Dec 11, 2026 (Est.)RDOUTCLYMBudoprutug (TNT119)—Phase 2
Dec 11, 2026 (Est.)RDOUTDMACRinvecalinase Alfa (DM199) - (ReMEDy2)—Phase 2
Dec 11, 2026 (Est.)RDOUTMGTXAAV2-hAQP1 - (AQUAx2)—Phase 2
Dec 11, 2026 (Est.)RDOUTRGNXSurabgene lomparvovec (sura-vec, ABBV-RGX-314) - (ATMOSPHERE)—Phase 2
Dec 11, 2026 (Est.)RDOUTROIVMosliciguat - (PHocus)—Phase 2
Dec 11, 2026 (Est.)RDOUTAPGEAPG279 (APG777+APG990)—Phase 1
Dec 11, 2026 (Est.)RDOUTBMYRYZ101 - (ACTION-1)—Phase 1
Dec 11, 2026 (Est.)RDOUTCGEMCLN-978 - (OUTRACE SLE)—Phase 1
Dec 11, 2026 (Est.)RDOUTFDMT4D-710 - (AEROW)—Phase 1
Dec 11, 2026 (Est.)RDOUTIMMXNXC-201 (HBI10101) - (NEXICART-2)—Phase 1
Dec 11, 2026 (Est.)RDOUTLXEOLX2020 - (HEROIC-PKP2)—Phase 1
Dec 11, 2026 (Est.)RDOUTNXTCLNCB74—Phase 1
Dec 11, 2026 (Est.)RDOUTPMNPMN310 - (PRECISE-AD)—Phase 1
Dec 11, 2026 (Est.)RDOUTZYMEZW191—Phase 1
Dec 18, 2026PDUFADCPHTirabrutinib81.4%TIER_2
Dec 22, 2026 (Est.)RDOUTADVMIxo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)—Phase 3
Dec 30, 2026 (Est.)RDOUTNTHINEO100-01—Phase 2
Dec 30, 2026 (Est.)RDOUTTCRXTSC-202-A0201—Phase 1
Dec 31, 2026 (Est.)RDOUTVIRTobevibart and Elebsiran - (ECLIPSE-1)—Phase 3
Dec 31, 2026 (Est.)RDOUTMNOVMN-001 (Tipelukast) - (NATG-202)—Phase 2
Dec 31, 2026 (Est.)RDOUTPBYIAlisertib - (PUMA-ALI-4201) - (ALISCA-Lung1)—Phase 2
Dec 31, 2026 (Est.)RDOUTGILDIDE397 + Trodelvy (sacituzumab-govitecan-hziy)—Phase 1
Dec 31, 2026 (Est.)RDOUTIDYAIDE397 + Trodelvy (sacituzumab-govitecan-hziy)—Phase 1
Mar 1, 2027 (Est.)PH3LXRXSotagliflozin—Phase 3
Jun 1, 2027 (Est.)PH3BMYCobenfy (xanomeline-trospium)—Phase 3
Showing 263 of 263 catalysts

PDUFA.BIO

FDA catalyst intelligence powered by the ODIN v1108 scoring engine. Trained on 2,200+ PDUFA decisions & 2,000+ phase readouts (2015–2026).

PLATFORM

DashboardCalendarScreenerRunup StrategyTrack RecordPaper TradeToolsPricing

LEARN

What Is a PDUFA Date?GlossaryResearchAbout ODINData SourcesPartnersAdvertiseAPIDisclaimer

PDUFA.BIO is the data-driven FDA PDUFA calendar and biotech catalyst calendar built for quantitative investors. Track upcoming PDUFA dates for 2026, FDA drug approval action dates, and biotech earnings dates in a unified, filterable calendar. Learn what a PDUFA date is and how the ODIN AI scoring engine generates FDA approval probability scores. Use the biotech catalyst screener to filter by ticker, therapeutic area, and ODIN tier. Explore the PDUFA runup strategy and verify ODIN's accuracy on the verified track record page. Browse our biotech glossary and catalyst research hub.

DISCLAIMER: PDUFA.BIO is not affiliated with, endorsed by, or connected to the U.S. Food & Drug Administration (FDA) or any government agency. The name "PDUFA" refers to the Prescription Drug User Fee Act and is used descriptively. This site does not provide financial, investment, legal, or medical advice. PDUFA.BIO is not a registered investment advisor, broker-dealer, or financial planner. Probability scores are generated by machine-learning models based on historical data and publicly available information. These scores are statistical estimates, not predictions or guarantees of FDA action or securities performance. Past approval rates do not guarantee future results.

RISK WARNING: Investing in biotechnology and pharmaceutical securities involves substantial risk, including the risk of total loss of capital. Binary catalyst events (such as PDUFA dates) can result in extreme price volatility. You should not invest money you cannot afford to lose. Always consult with a qualified financial advisor before making investment decisions. PDUFA.BIO, its operators, contributors, and affiliates accept no responsibility or liability for any losses arising from use of this site.

© 2026 PDUFA.BIO — All rights reserved.Market data via FMP · Social data via LunarCrush